Skip to main content

Table 5 Cost-effectiveness analysis for alternative scenarios

From: Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache

 Treatment group Mean cost, € Mean QALY ICERa
Constant rate of response loss
 nVNS + SoC 7377.41 0.558 nVNS dominant over SoCb
 SoC alone 7518.56 0.526
Diminishing rate of response loss
 nVNS + SoC 7141.30 0.599 nVNS dominant over SoCb
 SoC alone 7508.98 0.525
No response for SoC
 nVNS + SoC 7085.34 0.610 nVNS dominant over SoCb
 SoC alone 7507.94 0.524
  1. Abbreviations: ICER incremental cost-effectiveness ratio, nVNS non-invasive vagus nerve stimulation, QALY quality-adjusted life-year, SoC standard of care
  2. Probabilistic estimates are based on mean results across all Monte Carlo simulations [21]
  3. aThe expense of gaining an additional QALY with adjunctive nVNS therapy (vs SoC alone)
  4. bIndicates that adjunctive nVNS therapy was more effective and cost saving than SoC alone